CMS releases 2027 Medicare cost-sharing parameters: what pricing teams should check first
The 2027 Part A, B and Part D income-adjustment parameters are out, but the figures were not in the material we reviewed. Next to a fraud-focused proposed rule, they frame US payer planning.
What happened
On 17 November 2026 the US Centers for Medicare & Medicaid Services (CMS) published its 2027 Medicare cost-sharing parameters. The release covers Part A and Part B premiums and deductibles, plus income-related adjustments in Part D. The text available to us did not include the actual figures, so this analysis does not quote any premium, deductible or income threshold. Readers should take the numbers directly from the CMS fact sheet before updating any model.
The publication is an annual administrative step, not a policy proposal. It still matters because these parameters set what beneficiaries pay out of pocket, and they feed into how Medicare coverage is experienced and budgeted.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Sources this analysis is based on
- CMS publishes 2027 Medicare Part A and B premiums, deductibles and Part D income-related adjustments CMS · Tue 17 Nov 2026
- AIFA publishes sunset clause pre-notice for medicines facing lapse in early 2027 AIFA · Tue 17 Nov 2026
- Estonia's medicines agency publishes 2026 statistical yearbook covering 2021–2025 market and use trends Ravimiamet · Tue 17 Nov 2026
- AIFA issues sunset clause pre-notice for products at risk of lapsing in early 2027 AIFA · Tue 17 Nov 2026
- China adds Ascentage's lisaftoclax to NRDL; olverembatinib coverage renewed after renegotiation Ascentage Pharma Group International · Mon 16 Nov 2026
- CMS publishes fact sheet on Fiscal Year 2026 improper payments CMS · Mon 16 Nov 2026
Written by VigiEye's editorial system with AI assistance (model claude-sonnet-5-5) strictly from the official records listed above. It can contain errors: check the sources before acting. Not legal, medical or investment advice.
Tablo power cord overheating alert shows how a simple instruction change becomes a PV control
FDA's early alert on Outset Medical's Tablo cords is a reminder that use-instruction updates depend on reporting, user follow-through and a clear view of what is still unknown.
Lantern Pharma's first TNBC site and Taiwan start meet a CEO exit and a $4.0M raise
Lantern Pharma reported trial milestones for LP-184 and LP-300 in the same release as a CEO resignation and a roughly $4.0M offering, a mix sponsors and CROs should read carefully.
EEA Decision 191/2026 extends six EU feed additive acts to EEA EFTA markets, minus Liechtenstein
The EEA Joint Committee has added six feed additive acts, including a monensin sodium renewal and a Duddingtonia flagrans approval, to Annex I. Market access teams should read it as a lesson in how EU rules reach EEA markets.